黃馨祥，世界上最富裕的醫生（價值?$ 200億）宣布：
Cancer Moonshot 2020: Patrick Soon-Shiong, the richest physician on earth (worth ~$20 billion) announced:
calls itself Cancer Moonshot 2020 and also includes academic institutions and insurers. Its leaders hope to get competing drug and biotech companies to work together on the combination treatments rather than developing their own compounds in isolation.
?
聽起來你wantta“跳舞與癌症” - 你怎麽編排的舞蹈？怎麽樣？一個億萬富翁企業家已經拉到一起製藥公司組成的聯盟，以加速什麽的研究人員認為，可能是對抗癌症的有力武器發展 - 新的藥物，利用人體的免疫係統，有效的組合。
所謂免疫療法有助於抵抗疾病的細胞攻擊腫瘤。然而，研究人員認為，他們可能工作最好當兩個，三個或多種藥物一起使用 - 鋪天蓋地腫瘤的細胞防禦來自各方麵的攻擊。
帕特裏克匯聚了一群淳菘自稱登月2020年也包括學術機構和保險公司。它的領導人希望得到競爭性藥物和生物技術公司的聯合治療一起工作，而不是發展自己的化合物隔離。
“這裏的主要貢獻是運行的組合研究，藥品從多個製藥公司在快速運轉的能力，”曼努埃爾·伊達爾戈，癌症中心的貝斯以色列女執事醫療中心在波士頓臨床主任說。 “有未經批準的藥物從不同的製藥公司聯合研究是不容易做到的，我們希望能夠結合三，四藥，而不是兩個。”
雖然免疫療法有自己的副作用，醫生都希望他們可以更好地適應患者的腫瘤的空間，有朝一日取代或補充化療，這被認為是為具有高毒性鈍工具。
該集團的目標是完成的臨床試驗達20腫瘤類型中為多達2萬??例，到2020年，根據在舊金山舉行的摩根大通保健大會發表了一份聲明。參與製藥公司安進公司包括公司，Celgene的公司，葛蘭素史克公司和NantWorks有限責任公司，以及醫療保險公司獨立藍十字和美國公司，這是自保險的銀行，根據該聲明。
拜登會議
該聯盟的成員會見了美國副總統約瑟夫·拜登，誰在一個“登月”，需要治愈癌症十一月份發表講話說，與淳菘會談後，拜登的講話來了，這位億萬富翁說，該聯盟還沒有問奧巴馬政府的財政支持，根據NantWorks。
所有的20000例患者都會有他們的腫瘤基因測序，該計劃是建立一個病人登記，其中製藥公司可以尋找適合的標準，他們的審判具體的患者，稱淳菘，NantWorks首席執行官。淳菘成為通過藥物公司，他開始了一個億萬富翁，銷售，APP製藥公司和Abraxis公司BioScience公司
“在大型製藥公司現在人們意識到，他們不能孤軍奮戰，”淳菘在接受采訪時說，該聯盟是在非常早期的階段，尚未確定還多少每個參與者可能提供財政捐助和集團如何將集體保持患者的數據庫，他說。
獨立藍十字會涉及與試驗為它的成員門診費用，也將涵蓋淳菘的公司NantHealth進行基因測序，根據女發言人伊麗莎白出售。費城為基礎的健康保險覆蓋1000萬人在34個州和華盛頓特區，根據其網站。
A billionaire entrepreneur has pulled together a coalition of drugmakers to speed development of what researchers believe could be a powerful weapon against cancers -- potent combinations of new drugs that harness the body’s immune system.
So-called immunotherapies help disease-fighting cells attack tumors. Yet researchers believe they may work best when two, three or more of the drugs are used together -- overwhelming a tumor’s cellular defenses with attacks from all sides.
The group brought together by Patrick Soon-Shiong calls itself Moonshot 2020 and also includes academic institutions and insurers. Its leaders hope to get competing drug and biotech companies to work together on the combination treatments rather than developing their own compounds in isolation.
“The key contribution here is the ability to run combination studies with drugs from multiple pharma companies in a rapid manner,” said Manuel Hidalgo, clinical director of the Cancer Center at Beth Israel Deaconess Medical Center in Boston. “Combination studies with unapproved drugs from different pharma companies are not easy to do, and we want to be able combine three to four drugs, not just two."
While the immunotherapies have side effects of their own, physicians have hoped they can be better tailored to a patient’s tumor profile, and someday replace or supplement chemotherapy, which is thought of as a blunt tool with high toxicity.
The group aims to complete clinical trials for up to 20 tumor types in as many as 20,000 patients by the year 2020, according to a statement issued at the J.P. Morgan Healthcare Conference in San Francisco. Participating drugmakers include Amgen Inc., Celgene Corp., GlaxoSmithKline Plc and NantWorks LLC, as well as health insurer Independence Blue Cross and Bank of America Corp., which is self-insured, according to the statement.
Biden Meeting
Members of the coalition met with U.S. Vice President Joseph Biden, who said in a November speech that a “moonshot" was needed to cure cancer. Biden’s speech came after meeting with Soon-Shiong, the billionaire said. The coalition hasn’t asked the Obama administration for financial support, according to NantWorks.
All 20,000 patients will have their tumors genetically sequenced, and the plan is to create a patient registry where drugmakers can search for specific patients that fit the criteria for their trials, said Soon-Shiong, chief executive officer of NantWorks. Soon-Shiong became a billionaire through drug companies he started and sold, APP Pharmaceuticals Inc. and Abraxis BioScience Inc.
“People in large pharma now realize they can’t go it alone," Soon-Shiong said in an interview. The coalition is in very early stages and hadn’t determined yet how much each participant might contribute financially and how the group would collectively maintain a database of patients, he said.
Independence Blue Cross will cover patient costs related to trials for its members, and will also cover genomic sequencing performed by Soon-Shiong’s company NantHealth, according to spokeswoman Elizabeth Sell. The Philadelphia-based health insurer covers 10 million people in 34 states and Washington, D.C., according to its website.
與癌共舞 （1）- 是時候了，停止人們死於癌症！澳大利亞 周家馨
| 推薦到群組
與癌共舞 （1）
- 是時候了，停止人們死於癌症！
澳大利亞 周家馨
今晨打開郵箱，看見從 the NCCN （the National Comprehensive Cancer Network，美國全方位癌症聯合會）發給我的一封郵件。因為我從 2013 年以來，一直是這個聯合會的會員。
美國奧巴馬總統和拜登副總統聯手，向全球的我們，吹起了向癌症宣戰的極強衝鋒號。
The NCCN 的 CEO Robert W. Carlson 宣告，“It is time that people stop dying of cancer."
是時候了，停止人們死於癌症！
郵件中還附了拜登副總統，親自給我們大家，寫的一封聲情並茂，感人肺腑的公開信。他46歲的大兒子波·拜登因腦癌，上周六逝世。
他說：
“ It’s personal for me. But it’s also personal for nearly every American, and millions of people around the world. We all know someone who has had cancer, or is fighting to beat it. They’re our family, friends, and co-workers.
這是對我有私人感觸的一件事，也是幾乎對每一個美國人有私人感觸的事，和對全世界千百萬人有私人感觸的事。我們全都知道，認識，一個患過癌症的人，或者正在與癌症抗爭，想要戰勝癌症的人。 他們是我們的家庭，朋友，和共事的人。”
.......
我就可以證實，這也是對我，有很深的私人感觸的一件事。我會在有機會的時候，與大家分享共勉。
讓癌症細胞，在下了決心要戰勝它的主人麵前，發抖吧。
周家馨
2016-01-14
寫於布裏斯本家中
http://blog.sciencenet.cn/blog-2981069-950365.html 此文來自科學網周家馨博客，轉載請注明出處。
上一篇：七十抒懷，答謝網友 澳大利亞 周家馨 2016-01-09
1 李勝文
發表評論 評論 (2 個評論)
- [2]李勝文
- "癌症的起因搞清了嗎？這就讓癌細胞發抖？" Sounds you wantta "dance with cancer" - How do you choreograph your dancer? HOW?
- [1]印大中
- 癌症的起因搞清了嗎？這就讓癌細胞發抖？
- ~~~~~~~~~~~~~~~~~~~~~~~
- A Billionaire's Cancer Moonshot
Patrick Soon-Shiong.
Photographer: Danny Moloshok/AP-
Amgen, Celgene, GSK, Independence Blue Cross join coalition
-
`Moonshot' group aims for trials in 20,000 patients by 2020
A billionaire entrepreneur has pulled together a coalition of drugmakers to speed development of what researchers believe could be a powerful weapon against cancers -- potent combinations of new drugs that harness the body’s immune system.
So-called immunotherapies help disease-fighting cells attack tumors. Yet researchers believe they may work best when two, three or more of the drugs are used together -- overwhelming a tumor’s cellular defenses with attacks from all sides.
The group brought together by Patrick Soon-Shiong calls itself Moonshot 2020 and also includes academic institutions and insurers. Its leaders hope to get competing drug and biotech companies to work together on the combination treatments rather than developing their own compounds in isolation.
“The key contribution here is the ability to run combination studies with drugs from multiple pharma companies in a rapid manner,” said Manuel Hidalgo, clinical director of the Cancer Center at Beth Israel Deaconess Medical Center in Boston. “Combination studies with unapproved drugs from different pharma companies are not easy to do, and we want to be able combine three to four drugs, not just two."
While the immunotherapies have side effects of their own, physicians have hoped they can be better tailored to a patient’s tumor profile, and someday replace or supplement chemotherapy, which is thought of as a blunt tool with high toxicity.
The group aims to complete clinical trials for up to 20 tumor types in as many as 20,000 patients by the year 2020, according to a statement issued at the J.P. Morgan Healthcare Conference in San Francisco. Participating drugmakers include Amgen Inc., Celgene Corp., GlaxoSmithKline Plc and NantWorks LLC, as well as health insurer Independence Blue Cross and Bank of America Corp., which is self-insured, according to the statement.
Biden Meeting
Members of the coalition met with U.S. Vice President Joseph Biden, who said in a November speech that a “moonshot" was needed to cure cancer. Biden’s speech came after meeting with Soon-Shiong, the billionaire said. The coalition hasn’t asked the Obama administration for financial support, according to NantWorks.
All 20,000 patients will have their tumors genetically sequenced, and the plan is to create a patient registry where drugmakers can search for specific patients that fit the criteria for their trials, said Soon-Shiong, chief executive officer of NantWorks. Soon-Shiong became a billionaire through drug companies he started and sold, APP Pharmaceuticals Inc. and Abraxis BioScience Inc.
“People in large pharma now realize they can’t go it alone," Soon-Shiong said in an interview. The coalition is in very early stages and hadn’t determined yet how much each participant might contribute financially and how the group would collectively maintain a database of patients, he said.
Independence Blue Cross will cover patient costs related to trials for its members, and will also cover genomic sequencing performed by Soon-Shiong’s company NantHealth, according to spokeswoman Elizabeth Sell. The Philadelphia-based health insurer covers 10 million people in 34 states and Washington, D.C., according to its website.
-
